Market research
HESTERBIO.NSE Hester Biosciences Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21B
- P/E ratio
- 15.2
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.42
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE782E01017
- Market cap
- 21B
- P/E ratio
- 15.2
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.42
About
About Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming products, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, farm hygiene, vitamins, minerals, and specialty feed supplements for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides Silvectant, a hydrogen peroxide and silver nitrate solution for disinfection of poultry sheds; Hestbac, a probiotic supplement to control pathogenic bacteria; Hestflora, a combined probiotic and prebiotic formulation that supports gut health and performance; AmmoStop, a probiotic blend for odour control and respiratory comfort in poultry farms. It also offers INACTIVATED H9N2 vaccine for low pathogenic avian influenza; ICEFT RTU, a ceftiofur formulation for uterine and bacterial infections; and Inomilk Gel, an oral calcium supplement, as well as operates diagnostic labs for poultry. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HESTERBIO.NSE discussion.
5 years, 4 months ago
Hester Biosciences Limited is currently in a long term uptrend where the price is trading 26.5% above its 200 day moving average.
From a valuation standpoint, the stock is 75.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Hester Biosciences Limited's total revenue rose by 12.2% to $569M since the same quarter in the previous year.
Its net income has increased by 7.2% to $123M since the same quarter in the previous year.
Finally, its free cash flow grew by 8.8% to $312M since the same quarter in the previous year.
Based on the above factors, Hester Biosciences Limited gets an overall score of 4/5.